InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,318.00
(
0.95%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
81.97
(
0.00%
)
Bitcoin
69,095.98
(
-0.25%
)
Post# of 251939
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119690
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: miljenko post# 232532

Tuesday, 05/19/2020 1:59:44 PM

Tuesday, May 19, 2020 1:59:44 PM

Post# of 251939
ABUS—You’re preaching to the choir insofar as I’m not impressed by the AB-729 data either. (Did you notice the word, “not” in the second sentence of the second paragraph of #msg-155712858?)

At best, AB-729 has a flat dose response; at worst, AB-729 may not have any dose that provides both efficacy and safety (unless the 90mg dose, which has yet to be reported, threads the needle). Moreover (as previously posted), I’m not convinced that targeting HBsAg is the right way to seek a functional cure in HBV.

p.s. ABUS is +25% today as I’m typing (vs +51% in yesterday’s AH session). Cooler heads at work today.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up